Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
AUTOR(ES)
Ednie, Lois M.
FONTE
American Society for Microbiology
RESUMO
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 μg/ml for 300 pneumococci, irrespective of their β-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs ≤2.0 μg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the β-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=521909Documentos Relacionados
- Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents
- Antipneumococcal Activity of BMS 284756 Compared to Those of Six Other Agents
- Antipneumococcal Activity of Ertapenem (MK-0826) Compared to Those of Other Agents
- Antipneumococcal Activity of ABT-773 Compared to Those of 10 Other Agents
- Antipneumococcal Activities of Gemifloxacin Compared to Those of Nine Other Agents